This site uses cookies. By using this site you agree to receiving cookies. View Policy.
/https://files-crowdcube-com.s3.amazonaws.com/files/pitch_pics/original/201903/37fcbcb70d9ee88ef1e36cadc88437e0.png)
50% of vaccines are wasted, mainly due to poor refrigeration. Stablepharma's invention is designed to deliver a disruptive solution that can eliminate waste & supply life-saving vaccines to all without refrigeration. Proof of Concept has been achieved & investment is now sought for commercialisation.
- R&D completed Proof of Concept verified by a WHO accredited Laboratory
- Current project plan is Clinical Trials in Humans on a 12 month timeline
- Designed to be compatible with c. 90 existing and approved vaccines
- The WHO & NGO’s are on record for the acute need for stable vaccines
Idea
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201902/p_syringe_07af0bb04867ad018c91b5d9ba00814b.jpg "Using StablevaX® is simple – just add water to re hydrate the sponge that contains the correct dose of vaccine, whilst dehydrated the vaccine is totally stable and safe.")
Using StablevaX® is simple – just add water to re hydrate the sponge that contains the correct dose of vaccine, whilst dehydrated the vaccine is totally stable and safe.
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201902/p_nibsc_221e8ea620926c18a9053d75c084aad2.jpg "R&D completed with Proof of Concept verified at NIBSC - a WHO accredited Laboratory")
R&D completed with Proof of Concept verified at NIBSC - a WHO accredited Laboratory
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201902/p_bar_chart_3ebac5d49763946368229ae3682da119.jpg "This patented invention will allow vaccines to be transported & stored for years without refrigeration whilst complying with the protocols set by the WHO")
This patented invention will allow vaccines to be transported & stored for years without refrigeration whilst complying with the protocols set by the WHO
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201902/p_istock-boy_vac_18f20f5f639e6819ac76f5163e1d4483.jpg "The WHO & NGO’s are on record for the acute need for stable vaccines")
The WHO & NGO’s are on record for the acute need for stable vaccines
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201902/p_swiss_b87915e3dd9692034de54dd7f237a1b2.jpg "Pilot Scale production facilities will be located in Delemont, Switzerland under the management of Dr Anil Chawla")
Pilot Scale production facilities will be located in Delemont, Switzerland under the management of Dr Anil Chawla
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201902/p_madrid_ddcd07f8cb0fc5092f7999f72f0ab847.jpg "Under the supervision of our R&D Director Dr Arcadio Garcia de Castro we have R&D Laboratories & Toxicology facilities located in Madrid")
Under the supervision of our R&D Director Dr Arcadio Garcia de Castro we have R&D Laboratories & Toxicology facilities located in Madrid
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201902/istock-jrt_6a1dde78a1add45a3eda0cd786fb5bcd.jpg "Animal vaccines - we will investigate the early revenue potential in the animal vaccine market")
Animal vaccines - we will investigate the early revenue potential in the animal vaccine market
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201903/d3139c0b7e659b177dec9789460c6fe0.jpg "The WHO reports over 50% vaccine wastage - This invention is designed to deliver a disruptive solution to avoid refrigeration, eliminate waste providing life-saving vaccines to all who need them.")
The WHO reports over 50% vaccine wastage - This invention is designed to deliver a disruptive solution to avoid refrigeration, eliminate waste providing life-saving vaccines to all who need them.
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201902/p_banner_i_stock_fdfab201030254a9c83577f260c7f5ec.jpg "SP's first investor was Dr Inga Zaytseva, for us she encapsulated the ideal shareholder vision; ‘’I am investing in Stablepharma, 50% for the impact on World Health, and 50% because of the investment''")
SP's first investor was Dr Inga Zaytseva, for us she encapsulated the ideal shareholder vision; ‘’I am investing in Stablepharma, 50% for the impact on World Health, and 50% because of the investment''
'Every 20 seconds a child dies from a vaccine-preventable disease'
Gates Foundation
Problem: Vaccines are perishable, requiring constant & precise refrigeration from the manufacturer to the patient, be it in a UK Hospital or a clinic in Africa. The WHO estimates that c 50% of all vaccines are wasted in spite of c $400m p.a. spent on the global Cold Chain
Solution: this patented invention will allow vaccines to be transported & stored for years without refrigeration whilst complying with the protocols set by the WHO. It’s an important breakthrough that can save many lives.
Stablevax comprises approved vaccines which are dried from a solution of stabilising sugar into a special sponge stored in a normal syringe. They are pre-dosed and safe, to use you just add water. Stable vaccines will be manufactured at c. the same price as current products
£600k of equity funding enabled completion of R&D to the Proof of Concept milestone independently verified by the National Institute of Biological Standards and Controls (NHS & WHO-accredited Laboratory)
The current project plan involves the Tetanus vaccine processed through Clinical Trials in Humans, this achievement will significantly enhance the value of the invention and allow us to set up pilot scale production as the last step to commercialisation to enter the c. $36 bn human vaccine market and exploit this truly disruptive invention
THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE BY THE COMPANY RAISING FINANCE AS IDENTIFIED ABOVE (THE "COMPANY") IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY AND SUBJECT TO THESE TERMS AND CONDITIONS. CROWDCUBE CAPITAL LTD IS AUTHORISED BY THE FCA AND CARRIES OUT DUE DILIGENCE ON EACH COMPANY THAT LISTS ON CROWDCUBE AS SET OUT HERE.
This investment opportunity is not an offer to the public and is only available to registered members of Crowdcube.com who have qualified and categorised themselves as able to invest. The investment opportunity is not directed at persons located in the United States, Canada or Japan. Any person resident outside the United Kingdom who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict access.
In particular, unless otherwise determined by the Company and permitted by applicable law and regulation, it is not intended, subject to certain exceptions, that any offering of the securities mentioned in such materials (the "Securities") by the Company would be made, or any documentation be sent in or into, the United States, Canada or Japan. There will be no public offering of the Securities in the United States.
In order to access the pitch you must first become a qualifying member of Crowdcube on the basis of your status as either (i) self-certified ‘high net worth investor’, (ii) certified ‘sophisticated investor’, (iii) self-certified as a ‘sophisticated investor’ or (iv) certified as a ‘restricted investor’, in each case in accordance with the FCA’s Conduct of Business Sourcebook Chapter 4.7. Potential investors are encouraged to "cross examine" the Company by interactive due diligence and use of the available online forums to bring the "wisdom of the crowd" to bear. Accessing the pitch also means you agree to Crowdcube’s most recent website terms and conditions and investor terms and conditions, which include Crowdcube's limitation of liability.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Crowdcube’s or the Issuer’s press announcements and this information page do not constitute an offer to sell securities of the Company. Further, it does not constitute a recommendation by the Company, Crowdcube or any other party to sell or buy securities in the Company.
By registering or logging into Crowdcube.com to view the investment opportunity, you certify that you are legally entitled to view the investment opportunities, are an authorised investor and you agree to all applicable terms and conditions on this website, including this disclaimer.
To see the rest of the Stablepharma pitch, join now.
It’s free, quick and easy.
Already registered? Log in
To see the rest of the Stablepharma pitch, join now.
It’s free, quick and easy.
/https://files-crowdcube-com.s3.amazonaws.com/files/pitch_pics/original/201903/37fcbcb70d9ee88ef1e36cadc88437e0.png)
